Cargando…
P.508 COVID-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier B.V.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670888/ http://dx.doi.org/10.1016/j.euroneuro.2020.09.372 |
| _version_ | 1783610825619013632 |
|---|---|
| author | Kott, A. Daniel, D.G. |
| author_facet | Kott, A. Daniel, D.G. |
| author_sort | Kott, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7670888 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76708882020-11-18 P.508 COVID-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data Kott, A. Daniel, D.G. Eur Neuropsychopharmacol Article Published by Elsevier B.V. 2020-11 2020-11-17 /pmc/articles/PMC7670888/ http://dx.doi.org/10.1016/j.euroneuro.2020.09.372 Text en Copyright © 2020 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Kott, A. Daniel, D.G. P.508 COVID-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data |
| title | P.508 COVID-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data |
| title_full | P.508 COVID-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data |
| title_fullStr | P.508 COVID-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data |
| title_full_unstemmed | P.508 COVID-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data |
| title_short | P.508 COVID-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data |
| title_sort | p.508 covid-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670888/ http://dx.doi.org/10.1016/j.euroneuro.2020.09.372 |
| work_keys_str_mv | AT kotta p508covid19impactonentrysymptomseverityinschizophreniaclinicaltrialspreliminarydata AT danieldg p508covid19impactonentrysymptomseverityinschizophreniaclinicaltrialspreliminarydata |